RxDoctor Payments DataLook up a doctor →

Luis Cotto Santana, MD

Hematology & Oncology · San Juan, PRNPI 1760747216

Payments from drug & device makers

$23,249in general payments, 2019–2025

Across 998 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$2K
  • PBG Puerto Rico LLC$2K
  • AbbVie$2K
  • Novartis$1K
  • plus $11K from 45 others

What the payments were for

  • Food & beverage$22,20395%
  • Education$1,0465%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,249 in reported general payments places this provider in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$50,201
Medicare patients
117
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib60$958,054
XtandiEnzalutamide53$757,816
RevlimidLenalidomide35$688,790
ErleadaApalutamide35$524,952
PomalystPomalidomide20$462,321
ErivedgeVismodegib27$356,618
VerzenioAbemaciclib17$264,792
TagrissoOsimertinib Mesylate14$240,323
Abiraterone Acetate27$131,358
PromactaEltrombopag Olamine13$95,253
RetacritEpoetin Alfa-Epbx47$82,200
Sunitinib Malate12$58,047
DarzalexDaratumumab12$50,444
ProliaDenosumab20$35,799
Imatinib Mesylate36$33,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Retacrit, Eliquis$305$1,052,368120 claims
Astellas Pharma US IncXtandi$192$757,81653 claims
Bristol Myers SquibbRevlimid$18$688,79035 claims
Johnson & JohnsonErleada, Darzalex, Xarelto$2,959$593,31078 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$2,350$462,32120 claims
Genentech USA, Inc.Erivedge$1,132$356,61827 claims
AstraZenecaTagrisso$2,198$240,32314 claims
NovartisPromacta$1,455$95,25313 claims
AmgenProlia$1,230$35,79920 claims
AbbVieCreon$1,822$2,88011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →